631 Pharmacokinetics and pharmacodynamics study of TU2218, TGFβRI and VEGFR2 dual inhibitor in patients with advanced solid tumors

• Do-Youn Oh,
• Anthony W Tolcher,
• Kyu Pyo Kim,
• Hyesung Shin,
• Huntaek Kim,
• Soo Jin Kim,
• Eunsun Lee

Affiliations

Do-Youn Oh

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

Anthony W Tolcher

9NEXT Oncology, San Antonio, TX, USA

Kyu Pyo Kim

6Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Hyesung Shin

1TiumBio Co., Ltd, Seongnam, Gyeonggi-do, Republic of Korea

Huntaek Kim

1TiumBio Co., Ltd, Seongnam, Gyeonggi-do, Republic of Korea

Soo Jin Kim

1TiumBio Co., Ltd, Seongnam, Gyeonggi-do, Republic of Korea

Eunsun Lee

1TiumBio Co., Ltd, Seongnam, Gyeonggi-do, Republic of Korea